68Ga PSMA 11 PET MRI in Intermediate and High Risk Prostate Cancer - Claudia Zacharias

Claudia Zacharias presents Gallium 6 PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using 68Ga-PSMA-11 PET/MR.  She reviews the potential role of 68Ga-PSMA-11 PET/MR in primary prostate cancer and the hope to improve the localization of cancer within the prostate.

Biography:

Claudia Zacharias, MD, Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center, Stanford, California

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe